Italia markets closed

PMV Pharmaceuticals, Inc. (PMVP)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
10,03+0,48 (+5,03%)
Alla chiusura: 04:00PM EST
10,03 0,00 (0,00%)
Dopo ore: 04:01PM EST
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente9,55
Aperto9,44
Denaro3,96 x 900
Lettera11,38 x 800
Min-Max giorno9,18 - 10,17
Intervallo di 52 settimane8,99 - 25,10
Volume490.197
Media Volume624.788
Capitalizzazione458,024M
Beta (5 anni mensile)1,12
Rapporto PE (ttm)N/D
EPS (ttm)-1,43
Prossima data utili27 feb 2023 - 03 mar 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A34,00
  • GlobeNewswire

    PMV Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference

    CRANBURY, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President & Chief Executive Officer of PMV Pharmaceuticals, will participate in a virtual fireside chat at the 5th Annual Evercore ISI HealthCONx Conference, taking place November 29 – December 1, 2022. The company will al

  • GlobeNewswire

    PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights

    Enrollment continued in the Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation Phase 1b combination trial with Merck evaluating PC14586 with KEYTRUDA® (pembrolizumab) on track to initiate in 2022 Biotech industry veteran Dr. Carol Gallagher appointed to Board of Directors CRANBURY, N.J., Nov. 08, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology com

  • GlobeNewswire

    PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors

    CRANBURY, N.J., Nov. 04, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced the appointment of Carol Gallagher, Pharm.D., to its Board of Directors. Dr. Gallagher brings more than 30 years of biotech leadership and expertise in drug development and commercialization. She replaces Thilo Schroeder, Ph.D., who is stepping down from the Boar